Europe could beat U.S. in biopharma innovation

11/13/2009 | Wall Street Journal, The

Europe could overthrow the U.S. as a leader in the biotech-drug industry if U.S. lawmakers decide to shorten market exclusivity for brand-name biopharmaceuticals under health reform legislation, writes Benedetto Della Vedova, former member of the European Parliament. A proposal to provide five to seven years of protection would stifle innovation and diminish the chance of U.S. companies to be globally competitive, giving way for European firms to create the next generation of biologic drugs, Della Vedova writes.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN